Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, PR China.
Oncol Rep. 2011 Dec;26(6):1479-85. doi: 10.3892/or.2011.1428. Epub 2011 Aug 19.
Mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) appear to occur frequently and selectively in gliomas. Our aim was to assess whether IDH mutations are common in Chinese glioma patients and whether the mutations predict good response to concomitant chemoradiotherapy. In this study IDH1 and IDH2 mutations were detected in a series of 203 gliomas. IDH1 mutations were present in 75 of the 203 cases (36.9%) while IDH2 mutations in 5 of the 203 cases (2.5%). No tumor was mutated in both IDH1 and IDH2. IDH1/2 mutations were associated with prolonged overall survival in the whole series of patients exclusive of pilocytic astrocytoma (P<0.001), WHO grade Ⅱ patients who received no adjuvant therapy after surgery (P=0.014) and WHO grade Ⅲ patients who received concomitant chemoradiotherapy (standard schedule) after surgery (P=0.033). Furthermore, there was no correlation between IDH1/2 mutations and reponse to concomitant chemoradiotherapy in anaplastic gliomas. Our results suggest that IDH1 mutations also occur freuqently in Chinese glioma patients but the frequency of IDH1 mutations is below the findings reported by North American and European groups. Furthermore, we confirm the prognostic significance of IDH1/2 mutations in gliomas, but the mutations cannot predict a favorable response to concomitant chemoradiotherapy in anaplastic gliomas.
异柠檬酸脱氢酶 1 和 2 基因（IDH1 和 IDH2）的突变似乎经常且选择性地发生在胶质瘤中。我们的目的是评估 IDH 突变是否常见于中国胶质瘤患者，以及突变是否预测对同期放化疗的良好反应。在这项研究中，我们检测了 203 例胶质瘤中 IDH1 和 IDH2 的突变。203 例病例中有 75 例（36.9%）存在 IDH1 突变，203 例中有 5 例（2.5%）存在 IDH2 突变。没有肿瘤同时在 IDH1 和 IDH2 中发生突变。IDH1/2 突变与所有患者（不包括毛细胞星形细胞瘤）的总生存时间延长相关（P<0.001），术后未接受辅助治疗的 WHO 分级Ⅱ患者（P=0.014）和术后接受同期放化疗（标准方案）的 WHO 分级Ⅲ患者（P=0.033）。此外，IDH1/2 突变与间变性神经胶质瘤对同期放化疗的反应之间没有相关性。我们的结果表明，IDH1 突变在中国胶质瘤患者中也经常发生，但 IDH1 突变的频率低于北美和欧洲人群的报道。此外，我们证实了 IDH1/2 突变在胶质瘤中的预后意义，但突变不能预测间变性神经胶质瘤对同期放化疗的良好反应。
